Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 dose-ranging study in acute myocardial infarction
2013-003458-26Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of CSL112 in myocardial infarction (MI) (3 arms), sponsored by CSL Behring. Primary endpoint: Clinically important drug-induced liver injury. Started Mar 2014; status: completed.
02
Drugs
CSL112
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2013-003458-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003458-26.